PROKIDNEY CORP.

Social Capital Suvretta Holdings Corp. III, which traded on Nasdaq under the ticker DNAC, was a blank-check company sponsored by Social Capital Suvretta — a partnership between Social Capital and Suvretta Capital Management. The SPAC completed its IPO in 2021 and announced a business combination with ProKidney Corp. in January 2022, targeting the biotech and pharmaceutical sector. ProKidney is a clinical-stage regenerative medicine company developing autologous cell therapy for chronic kidney disease. The transaction has since closed, bringing ProKidney to the public markets through the SPAC structure. Sign up at SpacDesk for full filings, deal timelines, and analytics on this and every SPAC transaction.

SPAC Counterparty (1)